Understand the source comparison
IBD Peptides 2026 Update: Comparison of Mechanisms and Trial Results
BPC-157 VEGFR-2 upregulation, tight junction protein synthesis (occludin, claudin-1), angiogenesis Phase 2 RCT: 58% clinical response in Crohn's at 10mcg/kg SC daily (University of Zagreb, 2025) Subcutaneous injection No FDA-approved formulation; requires comp
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- BPC-157
- VEGFR-2 upregulation, tight junction protein synthesis (occludin, claudin-1), angiogenesis
- Phase 2 RCT: 58% clinical response in Crohn's at 10mcg/kg SC daily (University of Zagreb, 2025)
- Subcutaneous injection
- No FDA-approved formulation; requires compounding under research protocols
- KPV Tripeptide
- NF-κB inhibition via nuclear translocation, blocks inflammatory gene transcription
- Phase 2 RCT: 64% endoscopic improvement in UC at 5mg TID oral (NCT04532476, 2025)
- Oral (delayed-release)
- Rapid gastric degradation without enteric coating; not bioavailable as sublingual or unprotected oral
- Thymosin Beta-4
- Actin monomer binding, promotes cell migration and wound healing, ECM remodeling
- Pilot study: 61% MRI-based fistula improvement in perianal Crohn's at 30mg SC twice weekly (Johns Hopkins, 2025)
- Does not achieve complete fistula closure; adjunct only to standard therapy